Bioanalytical
Options in Advanced Therapeutic Monoclonal Antibody Analysis
Sep 18 2012
Author: by Ken Cook on behalf of Thermo Scientific
Protein Biopharmaceuticals–Challenges in Characterisation
Monoclonal antibody (mAb) biopharmaceuticals form the largest part of a growing biotherapeutics drug market and produced a requirement to develop new analytical characterisation methods. These large biomolecules are very different from the world of small molecule drugs and require different types of characterisation with very different methodology. Small molecules produce a limited number of impurities compared to a mAb which theoretically can have almost 10,000 variant molecules due to the size and complexity.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Apr 23 2024 Kintex, South Korea
Apr 23 2024 Seoul, South Korea
Apr 28 2024 Montreal, Quebec, Canada
May 05 2024 Seville, Spain
May 15 2024 Birmingham, UK
